DDInter1940 DDInter1118
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis.[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the E
Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers).
Vismodegib {u} (Compound) resembles {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Vismodegib {u} (Compound) resembles {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Fostemsavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Vismodegib {u} (Compound) resembles {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alimemazine
Alimemazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Vismodegib {u} (Compound) resembles {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Vismodegib {u} (Compound) resembles {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indomethacin
Indomethacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Vismodegib {u} (Compound) resembles {v} (Compound) Tolvaptan
Tolvaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Vismodegib {u} (Compound) treats {v} (Disease) skin cancer
skin cancer {u} (Disease) is treated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Vismodegib {u} (Compound) resembles {v} (Compound) Tolvaptan
Tolvaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Vismodegib {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Sevoflurane
Sevoflurane {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Vismodegib {u} (Compound) resembles {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Vismodegib (Compound) resembles Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Vismodegib (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Vismodegib (Compound) resembles Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Vismodegib (Compound) resembles Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Vismodegib (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Vismodegib (Compound) resembles Tolvaptan (Compound) and Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Vismodegib (Compound) treats skin cancer (Disease) and skin cancer (Disease) is treated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Vismodegib (Compound) resembles Tolvaptan (Compound) and Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Vismodegib (Compound) binds ALB (Gene) and ALB (Gene) is bound by Sevoflurane (Compound) and Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Vismodegib (Compound) resembles Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide